"EGFR mutations" trang 1 - tải miễn phí từ tailieunhanh
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
10    44    1
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
9    82    0
Establishing a molecular protocol for detection of EGFR mutations in patients with non-small cell lung cancer

Establishing a molecular protocol for detection of EGFR mutations in patients with non-small cell lung cancer
8    76    0
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation
14    59    0
Summary of Doctoral thesis in Medicine: Studying the mRNA expression of CIZ1b, VEGF genes and egfr mutations with merkel cell virus infection in patients with non- small cell lung cancer

Summary of Doctoral thesis in Medicine: Studying the mRNA expression of CIZ1b, VEGF genes and egfr mutations with merkel cell virus infection in patients with non- small cell lung cancer
32    51    1
Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia

Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia
7    74    1
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
11    33    1
Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems

Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems
7    53    2
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first line tyrosine kinase inhibitors: Brain metastasis and de novo T790M matters

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first line tyrosine kinase inhibitors: Brain metastasis and de novo T790M matters
11    21    1
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: A case report

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: A case report
4    63    0
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study
10    63    0
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: An observational study

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: An observational study
10    51    1
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study
8    48    1
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
8    74    1
Summary of Phd thesis: Clinical, subclinical features and resistance to tyrosine kinase inhibitor of lung cancer patients with EGFR mutations

Summary of Phd thesis: Clinical, subclinical features and resistance to tyrosine kinase inhibitor of lung cancer patients with EGFR mutations
29    119    0
báo cáo khoa học:

báo cáo khoa học: " Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC"
7    48    0
Characteristics of the pathological, immunohistochemical findings and EGFR gene mutation on biopsies in 193 lung cancer patients

Characteristics of the pathological, immunohistochemical findings and EGFR gene mutation on biopsies in 193 lung cancer patients
8    92    0
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
6    94    0
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
11    90    1
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
10    54    1